Simple aspiration technique to address voiding dysfunction associated with transurethral injection of dextranomer/hyaluronic acid copolymer.
Dextranomer/hyaluronic acid copolymer (Zuidex) is currently under Food and Drug Administration investigation for use as a transurethral bulking agent to treat female stress urinary incontinence secondary to intrinsic sphincter deficiency. Urethral obstruction is a recognized complication of bulking agents. We describe an aspiration method to address iatrogenic voiding dysfunction resulting from this therapy.
Petrou
Steven P
SP
Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.
Pak
Raymond W
RW
Lightner
Deborah J
DJ
D000368:Aged; D003911:Dextrans / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D007267:Injections / Q000009:adverse effects; D008875:Middle Aged; D019736:Prostheses and Implants / Q000009:adverse effects*; D013396:Suction / Q000379:methods; D014521:Urethra; D014524:Urethral Obstruction / Q000209:etiology* / Q000628:therapy; D014550:Urinary Incontinence, Stress / Q000628:therapy*
D003911:Dextrans; C094535:deflux; D006820:Hyaluronic Acid